tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

JCR Pharmaceuticals Reports Q1 FY2025 Financial Results with Positive Sales Growth

Story Highlights
JCR Pharmaceuticals Reports Q1 FY2025 Financial Results with Positive Sales Growth

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has shared an update.

JCR Pharmaceuticals reported its consolidated financial results for the first quarter of FY2025, showing a 5.2% increase in net sales compared to the previous year, despite recording an operating loss of 606 million yen. The company’s financial forecast for the fiscal year ending March 31, 2026, remains unchanged, with expectations of a 14.3% increase in net sales, indicating a positive outlook for future growth.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

More about JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. operates in the pharmaceutical industry, focusing on the development and production of biopharmaceuticals and regenerative medicine products. The company is listed on the Tokyo Stock Exchange and is known for its innovative approaches in drug development and its commitment to addressing unmet medical needs.

Average Trading Volume: 1,681,127

Technical Sentiment Signal: Hold

Current Market Cap: Yen87B

See more data about 4552 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1